ViiV Healthcare reports data from Phase I trial of HIV drug

UK-based pharmaceutical company ViiV Healthcare has reported data from a Phase I trial of its investigational formulation, cabotegravir ultra long-acting (CAB-ULA), for HIV treatment and prevention.